Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors

@inproceedings{BrownGlaberman2012RoleOD,
  title={Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors},
  author={Ursa A Brown-Glaberman and Alison T Stopeck},
  booktitle={Biologics : targets & therapy},
  year={2012}
}
Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major source of morbidity for cancer patients with bone metastases. The receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation and activity in normal bone physiology as well as cancer-induced bone resorption. The first commercially available drug that specifically targets and inhibits the RANKL pathway is denosumab, a fully human monoclonal antibody that binds and neutralizes RANKL… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Similar Papers

Loading similar papers…